A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus

Virology Journal

Volumn 7, Issue , 2010, Pages

  Chang, Haiyan ^a   Huang, Chaoyang ^a   Wu, Jian ^a   Fang, Fang ^a   Zhang, Wenjie ^e   Wang, Fuyan ^d   Chen, Ze ^a,b,c  

^a HUNAN NORMAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d The First People s Hospital of Changde City)   (China)

^e XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INFLUENZA VACCINE; VIRUS PROTEIN; CORE PROTEIN; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NP PROTEIN, INFLUENZA A VIRUS; RNA BINDING PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SPLEEN CELL; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BODY WEIGHT; DISEASE MODEL; GENETICS; IMMUNOLOGY; LUNG; MONONUCLEAR CELL; ORTHOMYXOVIRUS INFECTION; SECRETION; SPLEEN; SURVIVAL; VIROLOGY; VIRUS LOAD;

AVIAN INFLUENZA VIRUS; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; SPLEEN; SURVIVAL ANALYSIS; VACCINES, DNA; VIRAL CORE PROTEINS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 77955721110     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-197     Document Type: Article

References (41)

1. Influenza A (H5N1) in Hong Kong: an overview. JS Tam, Vaccine 2002 20 Suppl 2 77 81 10.1016/S0264-410X(02)00137-8 12110265
2. Confirmed Human Cases of Avian Influenza A (H5N1). http://www.who.int/ csr/disease/avian-influenza/country/en/
3. The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants. J Cinatl Jr M Michaelis HW Doerr, Med Microbiol Immunol 2007 196 181 190 10.1007/s00430-007-0042-5 17492465
4. H5N1 viruses and vaccines. K Subbarao C Luke, PLoS Pathog 2007 3 40 10.1371/journal.ppat.0030040 17335350
5. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. A van Maurik N Sabarth HS Dacho P Bruhl M Schwendinger BA Crowe P Noel Barrett O Kistner M Keith Howard, Vaccine 28 1778 1785 10.1016/j.vaccine.2009.12.008 20018265
6. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. LY Lee LA Ha do C Simmons MD de Jong NV Chau R Schumacher YC Peng AJ McMichael JJ Farrar GL Smith, et al. J Clin Invest 2008 118 3478 3490 18802496
7. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Jameson J Cruz M Terajima FA Ennis, J Immunol 1999 162 7578 7583 10358215
8. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. JH Kreijtz G de Mutsert CA van Baalen RA Fouchier AD Osterhaus GF Rimmelzwaan, J Virol 2008 82 5161 5166 10.1128/JVI.02694-07 18353950
9. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Q Chen H Kuang H Wang F Fang Z Yang Z Zhang X Zhang Z Chen, Virus Genes 2009 38 30 38 10.1007/s11262-008-0305-2 19067149
10. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. DJ Laddy J Yan M Kutzler D Kobasa GP Kobinger AS Khan J Greenhouse NY Sardesai R Draghia-Akli DB Weiner, PLoS One 2008 3 2517 10.1371/journal.pone.0002517 18575608
11. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. Y Chen K Qin WL Wu G Li J Zhang H Du MH Ng JW Shih JS Peiris Y Guan, et al. J Infect Dis 2009 199 49 58 10.1086/594374 19032063
12. A universal epitope-based influenza vaccine and its efficacy against H5N1. Y Adar Y Singer R Levi E Tzehoval S Perk C Banet-Noach S Nagar R Arnon T Ben-Yedidia, Vaccine 2009 27 2099 2107 10.1016/j.vaccine.2009.02.011 19356612
13. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Z Sui Q Chen R Wu H Zhang M Zheng H Wang Z Chen, Arch Virol 2010 155 535 544 10.1007/s00705-010-0621-4 20195654
14. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. JH Kreijtz R Bodewes JM van den Brand G de Mutsert C Baas G van Amerongen RA Fouchier AD Osterhaus GF Rimmelzwaan, Vaccine 2009 27 4983 4989 10.1016/j.vaccine.2009.05. 079 19538996
15. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. P Tao M Luo R Pan D Ling S Zhou P Tien Z Pan, Antiviral Res 2009 81 253 260 10.1016/j.antiviral. 2008.12.009 19135483
16. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. Z Vajo J Wood L Kosa I Szilvasy G Paragh Z Pauliny K Bartha I Visontay A Kis I Jankovics, J Virol 2010 84 1237 1242 10.1128/JVI.01894-09 19906909
17. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. D Ikeno K Kimachi Y Kino S Harada K Yoshida S Tochihara S Itamura T Odagiri M Tashiro K Okada, et al. Microbiol Immunol 2010 54 81 88 10.1111/j.1348-0421.2009.00191.x 20377741
18. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. JL Bresson C Perronne O Launay C Gerdil M Saville J Wood K Hoschler MC Zambon, Lancet 2006 367 1657 1664 10.1016/S0140-6736(06)68656-X 16714186
19. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. T Nolan PC Richmond NT Formica K Hoschler MV Skeljo T Stoney J McVernon G Hartel DC Sawlwin J Bennet, et al. Vaccine 2008 26 6383 6391 10.1016/j.vaccine.2008.08.046 18801398
20. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. JJ Treanor JD Campbell KM Zangwill T Rowe M Wolff, N Engl J Med 2006 354 1343 1351 10.1056/NEJMoa055778 16571878
21. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. I Stephenson KG Nicholson A Colegate A Podda J Wood E Ypma M Zambon, Vaccine 2003 21 1687 1693 10.1016/S0264-410X(02)00632-1 12639491
22. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. N Hehme H Engelmann W Kuenzel E Neumeier R Saenger, Virus Res 2004 103 163 171 10.1016/j.virusres.2004.02.029 15163505
23. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. SL Epstein TM Tumpey JA Misplon CY Lo LA Cooper K Subbarao M Renshaw S Sambhara JM Katz, Emerg Infect Dis 2002 8 796 801 12141964
24. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Z Chen Y Sahashi K Matsuo H Asanuma H Takahashi T Iwasaki Y Suzuki C Aizawa T Kurata S Tamura, Vaccine 1998 16 1544 1549 10.1016/S0264-410X(98)00043-7 9711802
25. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. M Qiu F Fang Y Chen H Wang Q Chen H Chang F Wang R Zhang Z Chen, Biochem Biophys Res Commun 2006 343 1124 1131 10.1016/j.bbrc.2006.03.088 16580631
26. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Z Chen S Kadowaki Y Hagiwara T Yoshikawa K Matsuo T Kurata S Tamura, Vaccine 2000 18 3214 3222 10.1016/S0264-410X(00)00149-3 10869766
27. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice. F Fang XQ Cai HY Chang HD Wang ZD Yang Z Chen, Acta Virol 2008 52 107 112 18564897
28. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. Z Chen T Yoshikawa S Kadowaki Y Hagiwara K Matsuo H Asanuma C Aizawa T Kurata S Tamura, J Gen Virol 1999 80 Pt 10 2559 2564 10573147
29. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. SL Epstein WP Kong JA Misplon CY Lo TM Tumpey L Xu GJ Nabel, Vaccine 2005 23 5404 5410 10.1016/j.vaccine.2005.04.047 16011865
30. CDC and Fort Dodge Animal Health Achieve First Licensed DNA Vaccine. http://www.cdc.gov/media/pressrel/r050718.htm
31. Melanoma vaccine for dogs. S Elvidge, Nature biotechnology 2010 28 189 10.1038/nbt0310-189a 20212469
32. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. RR MacGregor JD Boyer KE Ugen KE Lacy SJ Gluckman ML Bagarazzi MA Chattergoon Y Baine TJ Higgins RB Ciccarelli, et al. J Infect Dis 1998 178 92 100 9652427
33. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. LR Smith MK Wloch M Ye LR Reyes S Boutsaboualoy CE Dunne JA Chaplin D Rusalov AP Rolland CL Fisher, et al. Vaccine 2010 28 2565 2572 10.1016/j.vaccine.2010.01.029 20117262
34. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. TP Le KM Coonan RC Hedstrom Y Charoenvit M Sedegah JE Epstein S Kumar R Wang DL Doolan JD Maguire, et al. Vaccine 2000 18 1893 1901 10.1016/S0264-410X(99)00407-7 10699338
35. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. ST Rottinghaus GA Poland RM Jacobson LJ Barr MJ Roy, Vaccine 2003 21 4604 4608 10.1016/S0264-410X(03)00447-X 14575774
36. Preclinical and clinical safety studies on DNA vaccines. JA Schalk FR Mooi GA Berbers LA van Aerts H Ovelgonne TG Kimman, Hum Vaccin 2006 2 45 53 17012886
37. Evolution of avian influenza viruses. DL Suarez, Vet Microbiol 2000 74 15 27 10.1016/S0378-1135(00)00161-9 10799775
38. Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes. J Wu F Zhang F Fang H Chang F Wang Z Yang B Sun Z Chen, Vaccine 28 2775 2781 10.1016/j.vaccine.2010.01.037 20117261
39. Protection against influenza virus challenge by topical application of influenza DNA vaccine. S Watabe KQ Xin A Ihata LJ Liu A Honsho I Aoki K Hamajima B Wahren K Okuda, Vaccine 2001 19 4434 4444 10.1016/S0264-410X(01)00194-3 11483269
40. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. S Saha S Yoshida K Ohba K Matsui T Matsuda F Takeshita K Umeda Y Tamura K Okuda D Klinman KQ Xin, Virology 2006 354 48 57 10.1016/j.virol.2006.04.015 16945400
41. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Y Hagiwara K Komase Z Chen K Matsuo Y Suzuki C Aizawa T Kurata S Tamura, Vaccine 1999 17 2918 2926 10.1016/S0264-410X(99)00135-8 10438064